A neutralizing antibody P5S-1D8 that broadly neutralizes SARS-CoV-2 and its application

Abstract

The present invention discloses a neutralizing antibody P5S-1D8 for broad-spectrum neutralization of SARS-CoV-2 and its application. The present invention provides an IgG antibody, named P5S-1D8 antibody, which is composed of a light chain and a heavy chain; the CDR1, CDR2 and CDR3 in the heavy chain variable region in the heavy chain are shown in SEQ ID NO: 1, 26-33, 51-58 and 97-117, respectively; the CDR1, CDR2 and CDR3 in the light chain variable region in the light chain are shown in SEQ ID NO: 4, 26-34, 52-54 and 91-100, respectively. The P5S-1D8 antibody provided by the present invention has the effect of broad-spectrum neutralization of SARS-CoV-2, and has strong neutralization ability against wild-type novel coronavirus and natural variants. The present invention has great application value for the prevention and control of the novel coronavirus and will have far-reaching social significance.

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to a neutralizing antibody P5S-1D8 that broadly neutralizes SARS-CoV-2 and an application thereof. Background Art

[0002] COVID-19 infection is caused by the new coronavirus. The main symptoms are low-grade fever, fatigue and dry cough. A small number of patients also have upper respiratory and digestive tract symptoms such as nasal congestion, runny nose and diarrhea. Severe patients will develop acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction and multiple organ failure. The new coronavirus (SARS-CoV-2) belongs to the genus β coronavirus.

[0003] SARS-CoV-2 has produced many mutations during its transmission, which has enhanced its ability to spread and escape immunity. The main natural mutant strains currently in circulation include the Alpha strain found in the UK, the Beta strain found in South Africa, and the Gamma strain found in Brazil. Vaccine immunity against the new coronavirus has also been affected to a certain extent. The neutralizing activity of inactivated vaccine immune serum against the South African mutant strain has dropped by half, and the neutralizing activity of mRNA vaccine immune serum against the South African mutant strain has dropped by about 10 times. Many monoclonal antibodies have also weakened or lost their neutralizing activity against the mutant strain.

[0004] Monoclonal antibodies can be mass-produced industrially. Their high affinity and specificity for binding to antigens greatly reduce adverse reactions during clinical application. At the same time, antibody molecules can be modified to increase their antiviral efficacy. Antibodies have become a very promising means of treating infectious diseases due to their specificity and flexibility of use. At present, there is an urgent need to respond to the challenges brought by the natural mutant strains of the new coronavirus. The development of broad-spectrum human monoclonal antibodies against the new coronavirus will provide more effective prevention and treatment methods for infections caused by the natural mutant strains of the new coronavirus. Summary of the invention

[0005] The purpose of the present invention is to provide a neutralizing antibody P5S-1D8 that can broadly neutralize SARS-CoV-2 and an application thereof.

[0006] The present invention provides an IgG antibody, named P5S-1D8 antibody, which consists of a light chain and a heavy chain; CDR1, CDR2 and CDR3 in the heavy chain variable region of the heavy chain are shown in SEQ ID NO: 1 at positions 26-33, 51-58 and 97-117, respectively; CDR1, CDR2 and CDR3 in the light chain variable region of the light chain are shown in SEQ ID NO: 4 at positions 26-34, 52-54 and 91-100, respectively.

[0007] Specifically, the heavy chain variable region is shown in SEQ ID NO: 1.

[0008] Specifically, the light chain variable region is shown in SEQ ID NO:4.

[0009] Specifically, the heavy chain is as follows (a) or (b): (a) the protein shown at positions 20-477 in SEQ ID NO: 2; (b) the protein shown in SEQ ID NO: 2.

[0010] Specifically, the light chain is as follows (c) or (d): (c) the protein shown at positions 20-236 in SEQ ID NO:5; (d) the protein shown in SEQ ID NO:5.

[0011] The gene encoding the IgG antibody also falls within the protection scope of the present invention.

[0012] Specifically, the gene encoding the heavy chain is as follows (1) or (2):

[0013] (1) the DNA molecule represented by nucleotides 949-2325 of SEQ ID NO: 3;

[0014] (2) The DNA molecule represented by nucleotides 892-2325 in SEQ ID NO:3.

[0015] Specifically, the gene encoding the light chain is as follows (3) or (4):

[0016] (3) the DNA molecule represented by nucleotides 1095-1748 of SEQ ID NO: 6;

[0017] (4) The DNA molecule represented by nucleotides 1038 to 1748 in SEQ ID NO:6.

[0018] The present invention also protects the use of any of the above-mentioned IgG antibodies in the preparation of drugs for inhibiting the new coronavirus.

[0019] The present invention also protects a drug for inhibiting the new coronavirus, the active ingredient of which is any of the above-mentioned IgG antibodies.

[0020] The present invention also protects the use of any of the above-mentioned IgG antibodies in the preparation of drugs for neutralizing the new coronavirus.

[0021] The present invention also protects a drug for neutralizing the new coronavirus, the active ingredient of which is any of the above-mentioned IgG antibodies.

[0022] The present invention also protects the use of any of the above-mentioned IgG antibodies in the preparation of drugs for preventing and / or treating new coronavirus infections.

[0023] The present invention also protects a drug for preventing and / or treating COVID-19 infection, the active ingredient of which is any of the above-mentioned IgG antibodies.

[0024] Any of the above-mentioned new coronavirus infections is a new coronavirus infection.

[0025] Any of the above-mentioned novel coronaviruses is a wild-type novel coronavirus or a natural variant of the wild-type novel coronavirus.

[0026] Any of the above-mentioned novel coronaviruses is a novel coronavirus D614G mutant strain.

[0027] Any of the above-mentioned novel coronaviruses is a wild strain of the novel coronavirus, an Alpha strain of the novel coronavirus, a Beta strain of the novel coronavirus, a Gamma strain of the novel coronavirus, a Delta strain of the novel coronavirus, a Delta plus strain of the novel coronavirus, a Mu strain of the novel coronavirus or an Omicron strain of the novel coronavirus.

[0028] Specifically, the novel coronavirus Omicron strain is the novel coronavirus Omicron BA.1 strain, the novel coronavirus Omicron BA.2.12.1 strain, the novel coronavirus Omicron BA.2.75 strain, the novel coronavirus Omicron BA.3 strain or the novel coronavirus Omicron BA.4 / 5 strain.

[0029] The present invention uses the spike protein of the new coronavirus as bait, screens the memory B cells that produce antibodies from the peripheral blood mononuclear cells of the infected person, and obtains a monoclonal antibody that can specifically bind to the spike protein, named P5S-1D8 antibody. The P5S-1D8 antibody provided by the present invention has a broad spectrum of neutralization effects on SARS-CoV-2, and has strong neutralization ability against wild-type new coronaviruses and natural variants. The present invention has great application value for the prevention and control of the new coronavirus and will have far-reaching social significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The neutralizing activity of P5S-1D8 antibody against the new coronavirus pseudovirus. DETAILED DESCRIPTION

[0031] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0032] The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are carried out according to the techniques or conditions described in the literature in the art or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources. Unless otherwise specified, the quantitative tests in the following examples are set up for three repeated experiments, and the results are averaged. 293F cells and 293T cells are both commercially available human embryonic kidney epithelial cells. pMD18-T vector is a commercially available plasmid vector. pcDNA3.1(+) vector: Invitrogen, product catalog number V790-20.

[0033] hACE2-hela cells (ie "HeLa cell lines stably expressing theACE2molecules"), recorded in the following literature: Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Ch. en,P.,Liao,H.,Feng,Y.,Li,X.,Shi,X.,Zhang,Z.,Zhang,F.,Ding,Q.,Zhang,T.,Wang,X.&Zhang,L.Analysis of SARS-CoV-2 variant mutations reveal neutralization escape mechanisms and the ability to use ACE2receptors from additional species. Immunity 54, 1611-1621.e1615, doi:10.1016 / j.immuni.2021.06.003(2021).

[0034] Example 1. Discovery and preparation of P5S-1D8 antibody

[0035] 1. Discovery of P5S-1D8 Antibody

[0036] Memory B cells were isolated from peripheral blood mononuclear cells of patients in the recovery period of SARS-CoV-2, and the antibody genes of memory B cells were amplified to obtain antibody sequences. Through a large number of comparisons, analyses, preparations and effect verifications, the inventors of the present invention discovered a new SARS-CoV-2 IgG antibody with excellent activity, which was named P5S-1D8 antibody.

[0037] The amino acid sequence of the heavy chain variable region of the P5S-1D8 antibody is shown in SEQ ID NO: 1 (CDR1, CDR2 and CDR3 are located at positions 26-33, 51-58 and 97-117, respectively; CDR1, CDR2 and CDR3 are GFTFDDYA, VSWNSGTI, AKDSATRYYSGSDYTSYGMDV, respectively). The amino acid sequence of the full-length heavy chain of the P5S-1D8 antibody is shown in SEQ ID NO: 2; in SEQ ID NO: 2, amino acid residues at positions 1-19 constitute a signal peptide (to guide protein secretion outside the cell), amino acid residues at positions 20-147 constitute a heavy chain variable region, and amino acid residues at positions 148-477 constitute a heavy chain constant region.

[0038] The amino acid sequence of the light chain variable region of the P5S-1D8 antibody is shown in SEQ ID NO: 4 (CDR1, CDR2 and CDR3 is located at positions 26-34, 52-54, and 91-100, respectively; CDR1, CDR2, and CDR3 are SSDIGDYNY, DVS, SSYTSSSTVV, respectively). The amino acid sequence of the full-length light chain of the P5S-1D8 antibody is shown in SEQ ID NO: 5; in SEQ ID NO: 5, amino acid residues at positions 1-19 constitute a signal peptide (to guide protein secretion outside the cell), amino acid residues at positions 20-129 constitute a light chain variable region, and amino acid residues at positions 130-236 constitute a light chain constant region.

[0039] 2. Preparation of P5S-1D8 Antibody

[0040] (I) Construction of recombinant plasmid

[0041] The heavy chain DNA molecule is a double-stranded DNA molecule, as shown in SEQ ID NO: 3. In SEQ ID NO: 3, nucleotides 1-891 constitute a promoter, nucleotides 892-2325 encode a full-length heavy chain, and nucleotides 2326-2471 constitute a terminator. The heavy chain DNA molecule is inserted into the pMD18-T vector to obtain a heavy chain expression vector.

[0042] The light chain DNA molecule is a double-stranded DNA molecule, as shown in SEQ ID NO: 6. In SEQ ID NO: 6, nucleotides 1-1037 constitute a promoter, nucleotides 1038-1748 encode a full-length light chain, and nucleotides 1749-1896 constitute a terminator. The light chain DNA molecule is inserted into the pMD18-T vector to obtain a light chain expression vector.

[0043] (II) Construction of recombinant cells

[0044] The heavy chain expression vector and the light chain expression vector were co-transfected into 293F cells to obtain recombinant cells.

[0045] (III) Preparation of antibodies

[0046] 1. Take the recombinant cells obtained in step (ii), culture them in DMEM medium containing 2% fetal bovine serum for 72 hours, then centrifuge them at 4°C and 4000 rpm for 30 minutes, and collect the supernatant.

[0047] 2. Affinity chromatography

[0048] The column specifications for affinity chromatography are: length 3 cm, inner diameter 1 cm;

[0049] Column packing for affinity chromatography: protein A beads (Thermo, product catalog number 10006D);

[0050] Operation steps: ① Load 300 mL of the supernatant obtained in step 1 onto the affinity chromatography column and incubate at 4°C for 16 hours; ② Wash the column with 60 mL of binding buffer; ③ Elute the target protein with 30 mL of elution buffer and collect the solution after passing through the column.

[0051] Binding buffer: Take 112.6 g of glycine and 175.2 g of sodium chloride, dissolve them in water and make up to 1 L with water, and adjust the pH to 8.0 with sodium hydroxide.

[0052] Elution buffer: Take 7.5 g of glycine, dissolve it in water and make up to 500 ml with water, and adjust the pH to 3.0 with hydrochloric acid.

[0053] 3. Take the column solution obtained in step 2, concentrate it with an ultrafiltration concentration tube and replace the system with PBS buffer (pH 7.2, 10 mM) to obtain a P5S-1D8 antibody solution (antibody concentration is about 1 mg / ml).

[0054] Embodiment 2, neutralization test

[0055] 1. Preparation of novel coronavirus pseudovirus

[0056] The plasmid expressing the novel coronavirus membrane protein and the backbone plasmid pNL4-3R-E-luciferase were co-transfected into 293T cells. After incubation, a novel coronavirus pseudovirus with infectivity but no replication ability can be obtained. Its infectivity is the same asThe backbone plasmid pNL4-3R-E-luciferase, i.e., the backbone plasmid pNL4-3R-E containing Luciferase (i.e., the vector with the luciferase gene containing backbone pNL4-3R-E in the literature) is recorded in the following literature: Wang Q, Liu L, Ren W, Gettie A, Wang H, Liang Q, Shi X, Montefiori DC, Zhou T, Zhang L. Cell Rep. 2019.

[0057] The coding gene of the novel coronavirus membrane protein was inserted between the BamHII and EcoRI restriction sites of the pcDNA3.1(+) vector to obtain a plasmid expressing the novel coronavirus membrane protein. The plasmid expressing the novel coronavirus membrane protein and the backbone plasmid pNL4-3R-E-luciferase were co-transfected into 293T cells, incubated at 37°C (using DMEM medium containing 10% fetal bovine serum), and the cell culture supernatant was collected 60 hours after transfection to obtain the virus liquid containing the novel coronavirus pseudovirus. Virus liquids of pseudoviruses of 12 novel coronavirus strains were prepared separately. The 12 new coronavirus strains refer to the new coronavirus D614G mutant strain, the new coronavirus Alpha strain, the new coronavirus Beta strain, the new coronavirus Gamma strain, the new coronavirus Delta strain, the new coronavirus Delta plus strain, the new coronavirus Mu strain, the new coronavirus Omicron BA.1 strain, the new coronavirus Omicron BA.2.12.1 strain, the new coronavirus Omicron BA.2.75 strain, the new coronavirus Omicron BA.3 strain and the new coronavirus Omicron BA.4 / 5 strain.

[0058] The membrane protein of the wild-type coronavirus (WT) is shown in SEQ ID NO: 7. The gene encoding the membrane protein of the wild-type coronavirus is recorded in GenBank: MN908947.3 (18-MAR-2020) at positions 21563-25384 in the whole genome.

[0059] The membrane protein of the novel coronavirus D614G mutant strain has the following mutation relative to the membrane protein of the wild-type strain: D614G. The gene encoding the membrane protein of the novel coronavirus D614G mutant strain is shown in SEQ ID NO: 8.

[0060] The membrane protein of the novel coronavirus Alpha strain (Pango lineage B.1.1.7) has the following mutations compared to the membrane protein of the wild strain: 69-70del (HV), 144del (Y), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H. The gene encoding the membrane protein of the novel coronavirus Alpha strain is recorded in GISAID:EPI_ISL_601443.

[0061] The membrane protein of the novel coronavirus Beta strain (Pango lineage B.1.351) has the following mutations compared to the membrane protein of the wild strain: L18F, D80A, D215G, 242-244del (LLA), S305T, K417N, E484K, N501Y, D614G, A701V. The gene encoding the membrane protein of the novel coronavirus Beta strain is recorded in GISAID:EPI_ISL_700450.

[0062] The membrane protein of the novel coronavirus Gamma strain (Pango lineage P.1) has the following mutations compared to the membrane protein of the wild strain: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F. The gene encoding the membrane protein of the novel coronavirus Gamma strain is recorded in GISAID:EPI_ISL_792681.

[0063] Membrane protein of the novel coronavirus Delta strain (Pango lineage B.1.617.2) relative to that of the wild strain The following mutations occurred in the membrane protein: T19R, G142D, 156-157del (EF), R158G, A222V, L452R, T478K, D614G, P681R, D950N. The gene encoding the membrane protein of the novel coronavirus Delta strain is recorded in GISAID:EPI_ISL_1534938.

[0064] The membrane protein of the novel coronavirus Delta plus strain (Pango lineage AY.x) has the following mutation compared to the membrane protein of the Delta strain: K417N. The gene encoding the membrane protein of the novel coronavirus Delta plus strain is recorded in GISAID:EPI_ISL_3019629.

[0065] The membrane protein of the new coronavirus Mu strain (Pango lineage B.1.621) has the following mutations compared to the membrane protein of the wild strain: T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H, D950N. The gene encoding the membrane protein of the new coronavirus Mu strain is recorded in GISAID:EPI_ISL_3987640.

[0066] Novel coronavirus Omicron BA.1 strain (Pango lineage The membrane protein of BA.1) underwent the following mutations relative to that of the wild strain: A67V, Δ69-70 (HV), T95I, G142D, Δ143-145 (VYY), Δ211 (N), L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F. The gene encoding the membrane protein of the novel coronavirus Omicron BA.1 strain is recorded in GISAID:EPI_ISL_6752027.

[0067] The membrane protein of the new coronavirus Omicron BA.2.12.1 strain (Pango lineage BA.2.12.1) has undergone the following mutations relative to the membrane protein of the wild strain: T19I, 24-26del (LPP), A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K. The gene encoding the membrane protein of the new coronavirus Omicron BA.2.12.1 strain is recorded in GISAID:EPI_ISL_12560123.

[0068] The membrane protein of the new coronavirus Omicron BA.2.75 strain has undergone the following mutations relative to the membrane protein of the wild strain: T19I, del24-26 (LPP), A27S, G142D, K147E, W152R, F157L, I210V, V213G, G257S, G339H, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K. The gene encoding the membrane protein of the new coronavirus Omicron BA.2.75 strain is recorded in GISAID:EPI_ISL_14393635.

[0069] The membrane protein of the novel coronavirus Pango lineage BA.3 has the following mutations compared to the membrane protein of the wild-type strain: A67V, del69-70 (HV), T95I, G142D, del143-145 (VYY), 211del (N), L212I, G339D, S371F, S373P, S375F, D405N, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The coding gene of the membrane protein of the novel coronavirus Pango lineage BA.3 Recorded in GISAID:EPI_ISL_7740765.

[0070] The membrane protein of the novel coronavirus Omicron BA.4 / 5 strain (Pango lineage BA.4) has undergone the following mutations relative to the membrane protein of the wild strain: T19I, 24-26del (LPP), A27S, del69-70 (HV), G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The gene encoding the membrane protein of the novel coronavirus Omicron BA.4 / 5 strain is recorded in EPI_ISL_12559461.

[0071] 2. Neutralizing activity detection of antibodies

[0072] Test virus solutions: virus solutions of the 12 pseudovirus strains of the novel coronavirus prepared in step 1.

[0073] 1. Take the P5S-1D8 antibody solution prepared in Example 1 and dilute it with PBS buffer (pH 7.2, 10 mM) to obtain antibody dilutions of various concentrations.

[0074] 2. Take a 96-well cell culture plate and add 100 μl of antibody diluent and 50 μl of test virus solution to each well (the virus concentration in 50 μl of test virus solution is 1×10 4 TCID50 / ml), incubate at 37°C for 1 hour. Replace the antibody diluent with an equal volume of PBS buffer (pH 7.2, 10 mM) as a virus control. Replace the test virus solution with an equal volume of DMEM medium containing 10% fetal bovine serum as a cell control.

[0075] 3. After completing step 2, take the cell culture plate and inoculate 100 μl of hACE2-hela cell suspension in each well (the solvent used to prepare the cell suspension is DMEM medium containing 10% fetal bovine serum, and the concentration of hACE2-hela cells in the cell suspension is 2×10 5 cells / ml) and incubated at 37°C for 64 hours.

[0076] 4. After completing step 3, take the cell culture plate, discard the supernatant, add 150 μl of lysis buffer (Micrograss Biotechnology, product number T003, follow the instructions) to each well, and incubate at 37°C for 5 minutes.

[0077] 5. After completing step 4, take the cell culture plate and detect the luciferase activity.

[0078] Multiple replicate wells were set up for each treatment.

[0079] Neutralization activity (%) = [1-(fluorescence intensity of the test group-fluorescence intensity of the cell control) / (fluorescence intensity of the virus control-fluorescence intensity of the cell control)] x 100%.

[0080] Neutralization activity results are shown in Figure 1 . Figure 1 Middle: The ordinate is the neutralization activity (%); the abscissa is the logarithm of the antibody concentration (μg / ml) to the base 10, and the antibody concentration refers to the antibody concentration in the mixed system consisting of 100 μl of antibody diluent and 50 μl of test virus solution in step 2.

[0081] Prism 5 software was used to calculate the antibody concentration at which the neutralization activity was 50%, i.e., the IC50 value of the antibody.

[0082] The IC50 values ​​(unit: ng / ml) of the P5S-1D8 antibody against pseudoviruses of 12 novel coronavirus strains are shown in Table 1.

[0083] Table 1

[0084]

[0085]

[0086] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.

Claims

1. An IgG antibody, consisting of a light chain and a heavy chain; the CDR1, CDR2 and CDR3 in the heavy chain variable region of the heavy chain are shown in SEQ ID NO: 1 at positions 26-33, 51-58 and 97-117, respectively; the CDR1, CDR2 and CDR3 in the light chain variable region of the light chain are shown in SEQ ID NO: 4 at positions 26-34, 52-54 and 91-100, respectively.

2. The IgG antibody according to claim 1, characterized in that: The heavy chain variable region is shown in SEQ ID NO: 1; The light chain variable region is shown in SEQ ID NO:

4.

3. The IgG antibody according to claim 2, characterized in that: The heavy chain is (a) or (b): (a) the protein shown at positions 20-477 in SEQ ID NO: 2; (b) the protein shown in SEQ ID NO: 2; The light chain is (c) or (d) as follows: (c) the protein shown at positions 20 to 236 of SEQ ID NO:5; (d) the protein shown by SEQ ID NO:

5.

4. A gene encoding the IgG antibody according to any one of claims 1 to 3.

5. Use of the IgG antibody according to claim 1, 2 or 3 in the preparation of a drug for inhibiting the new coronavirus.

6. A drug for inhibiting the new coronavirus, wherein the active ingredient is the IgG antibody according to claim 1, 2 or 3.

7. Use of the IgG antibody according to claim 1, 2 or 3 in the preparation of a medicament for neutralizing the new coronavirus.

8. A drug for neutralizing the new coronavirus, the active ingredient of which is the IgG antibody described in claim 1, 2 or 3.

9. Use of the IgG antibody according to claim 1, 2 or 3 in the preparation of a medicament for preventing and / or treating COVID-19 infection.

10. A drug for preventing and / or treating COVID-19 infection, wherein the active ingredient is the IgG antibody according to claim 1, 2 or 3.

Images